Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Verena Schlintl"'
Autor:
Florian Posch, Luka Brčić, Gudrun Absenger, Verena Schlintl, Nikolaus John, Robert Wurm, Philipp J Jost, Angelika Terbuch, Teresa Sassmann, Jörg Lindenmann, Melanie Fediuk, Philipp Douschan, Martin Zacharias, Lipika Kalson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background The use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue. Nevertheless, PD-L1 often fails to predict response to treatment. One possible ex
Externí odkaz:
https://doaj.org/article/7b357905ef25400b8600961cad6d9dc2
Autor:
Maximilian Hochmair, Angelika Terbuch, David Lang, Christian Trockenbacher, Florian Augustin, Bahil Ghanim, Dominik Maurer, Hossein Taghizadeh, Christoph Kamhuber, Robert Wurm, Jörg Lindenmann, Petra Braz, Tatjana Bundalo, Merjem Begic, Johanna Bauer, Patrick Reimann, Nino Müser, Florian Huemer, Verena Schlintl, Daniela Bianconi, Bernhard Baumgartner, Peter Schenk, Markus Rauter, Konrad Hötzenecker
Publikováno v:
Cancers, Vol 16, Iss 14, p 2586 (2024)
This was a retrospective study of the profile and initial treatments of adults diagnosed with early-stage (ES) non-small cell lung cancer (NSCLC) during January 2018–December 2021 at 16 leading hospital institutions in Austria, excluding patients e
Externí odkaz:
https://doaj.org/article/3e588c78b2714c87bb4a690e179356da
Autor:
Matthias Preusser, Erika Richtig, Florian Moik, Cihan Ay, Martin Pichler, Florian Posch, Armin Gerger, Lukas Koch, Thomas Bauernhofer, Thomas Winder, Dominik A Barth, Sarah Steinlechner, Marie-Christina Mayer, Amelie M Sandner, Franziska Berton, Verena Schlintl, Nikolaus John, Robert Wurm, Patrick Reimann, Christoph Wohlkönig, Philipp J Jost, Angelika Terbuch, Jakob Michael Riedl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background C reactive protein (CRP) kinetics have recently been suggested as predictive biomarkers for the efficacy of immune checkpoint inhibitor (ICI) therapy in selected cancer types. The aim of this study was to characterize early CRP kinetics as
Externí odkaz:
https://doaj.org/article/a40a1d9c33b346768e290b28474e9d93
Autor:
Verena Schlintl, Florian Huemer, Gabriel Rinnerthaler, Thomas Melchardt, Thomas Winder, Patrick Reimann, Jakob Riedl, Arno Amann, Wolfgang Eisterer, Franz Romeder, Gudrun Piringer, Aysegül Ilhan-Mutlu, Ewald Wöll, Richard Greil, Lukas Weiss
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Safety and efficacy of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction (GEJ) cancer could be demonstrated in predominantly Asian cohorts, whereas data in Western patients outside of clinical trials ar
Externí odkaz:
https://doaj.org/article/4eb806de63a04d64920beb1c085feb6d
Autor:
Florian Huemer, Gudrun Piringer, Verena Schlintl, Hubert Hackl, Gabriel Rinnerthaler, Josef Thaler, Richard Greil, Lukas Weiss
Publikováno v:
Cancers, Vol 12, Iss 10, p 2812 (2020)
Current National Comprehensive Cancer Network (NCCN) and European Society of Medical Oncology (ESMO) guidelines recommend regorafenib or trifluridine/tipiracil (TAS-102) for the third-line therapy of metastatic colorectal cancer (mCRC). In this analy
Externí odkaz:
https://doaj.org/article/0421393af93d411fb680db3dc71907e3
Autor:
Florian Huemer, Eckhard Klieser, Daniel Neureiter, Verena Schlintl, Gabriel Rinnerthaler, Franck Pagès, Amos Kirilovsky, Carine El Sissy, Wolfgang Iglseder, Franz Singhartinger, Tarkan Jäger, Adam Dinnewitzer, Nadja Zaborsky, Markus Steiner, Richard Greil, Lukas Weiss
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 9, p 2775 (2020)
Reports on the prognostic role of programmed death-ligand 1 (PD-L1) expression in rectal cancer are controversial. We investigated expression patterns and changes of PD-L1 in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Seve
Externí odkaz:
https://doaj.org/article/b9731d65fe5641bf89fc54dd31052cff
Autor:
Florian Huemer, Stefan Hecht, Bernhard Scharinger, Verena Schlintl, Gabriel Rinnerthaler, Konstantin Schlick, Ronald Heregger, Thomas Melchardt, Angela Wimmer, Iris Mühlbacher, Oliver Owen Koch, Daniel Neureiter, Eckhard Klieser, Sara Seyedinia, Mohsen Beheshti, Richard Greil, Lukas Weiss
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Purpose Perioperative chemotherapy with FLOT constitutes a standard of care approach for locally advanced, resectable gastric or gastro-esophageal junction (GEJ) cancer. We aimed at investigating anthropometric, CT-based and FDG-PET-based body compos
Publikováno v:
J Gastrointest Oncol
BACKGROUND: Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data from patients treated with ramucirumab and
Autor:
Gudrun Piringer, Gabriel Rinnerthaler, Verena Schlintl, Lukas Weiss, Richard Greil, Josef Thaler, Florian Huemer, Hubert Hackl
Publikováno v:
Cancers
Volume 12
Issue 10
Cancers, Vol 12, Iss 2812, p 2812 (2020)
Volume 12
Issue 10
Cancers, Vol 12, Iss 2812, p 2812 (2020)
Current National Comprehensive Cancer Network (NCCN) and European Society of Medical Oncology (ESMO) guidelines recommend regorafenib or trifluridine/tipiracil (TAS-102) for the third-line therapy of metastatic colorectal cancer (mCRC). In this analy
Autor:
Richard Greil, Amos Kirilovsky, Tarkan Jäger, Franck Pagès, Franz Xaver Singhartinger, Lukas Weiss, Daniel Neureiter, Florian Huemer, Markus Steiner, Nadja Zaborsky, A. Dinnewitzer, Gabriel Rinnerthaler, Wolfgang Iglseder, Verena Schlintl, Carine El Sissy, Eckhard Klieser
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, MDPI, 2020, 9 (9), pp.2775. ⟨10.3390/jcm9092775⟩
Volume 9
Issue 9
Journal of Clinical Medicine, Vol 9, Iss 2775, p 2775 (2020)
Journal of Clinical Medicine, MDPI, 2020, 9 (9), pp.2775. ⟨10.3390/jcm9092775⟩
Volume 9
Issue 9
Journal of Clinical Medicine, Vol 9, Iss 2775, p 2775 (2020)
Reports on the prognostic role of programmed death-ligand 1 (PD-L1) expression in rectal cancer are controversial. We investigated expression patterns and changes of PD-L1 in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Seve